Having trouble accessing articles? Reset your cache.

AZD5363: Phase I data

Data from a pair of open-label, dose-escalation, European and Japanese Phase I trials in a total of 92 patients showed that twice-daily

Read the full 222 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE